Fms‐like tyrosine kinase 3 (FLT 3) belongs to the receptor tyrosine kinase family and
expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in~ 30% of …

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid
and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target …

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in
the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor …

Therapeutic effects of FLT3 inhibitors have been reported in acute myeloid leukemia (AML)
with constitutively activating FLT3 mutations, including internal tandem duplication (ITD) and …

Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute
myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating …

Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute
myeloid leukemia (AML), which has been confirmed as an important drug target for AML …

FMS‐like tyrosine kinase 3 (FLT3) has been found to be mutated in~ 30% of acute myeloid
leukaemia patients. Small‐molecule inhibitors targeting FLT3 that are currently approved or …

An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic
alteration associated with poor prognosis in acute myeloid leukemia (AML). Although many …

The FMS-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase that
is expressed in hematopoietic stem cells. The mutations of FLT3 gene found in 30% of acute …

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML. Thirty percent
of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either …